Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + Fludarabine
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Trial Timeline
Jan 25, 2018 → Nov 25, 2024
NCT ID
NCT03391466About Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + Fludarabine
Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + Fludarabine is a phase 3 stage product being developed by Gilead Sciences for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). The current trial status is completed. This product is registered under clinical trial identifier NCT03391466. Target conditions include Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).
What happened to similar drugs?
0 of 9 similar drugs in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) were approved
Approved (0) Terminated (1) Active (8)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03391466 | Phase 3 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)